Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
314.7 USD -1.35% Intraday chart for Amgen Inc. +0.59% +9.27%
May. 16 Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment DJ
May. 16 Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 143,240 133,852 126,718 140,139 154,142 168,827 - -
Enterprise Value (EV) 1 164,232 156,191 151,990 169,779 207,811 217,296 212,339 208,040
P/E ratio 18.7 x 18.7 x 21.9 x 21.7 x 23.1 x 40.7 x 25 x 23.9 x
Yield 2.41% 2.78% 3.13% 2.95% 2.96% 2.95% 3.17% 3.35%
Capitalization / Revenue 6.13 x 5.26 x 4.88 x 5.32 x 5.47 x 5.11 x 4.97 x 4.86 x
EV / Revenue 7.03 x 6.14 x 5.85 x 6.45 x 7.37 x 6.58 x 6.25 x 5.99 x
EV / EBITDA 12.3 x 9.8 x 9.61 x 10.5 x 11.9 x 11.4 x 10.9 x 10.5 x
EV / FCF 19.2 x 15.8 x 18.1 x 19.3 x 28.2 x 14.3 x 16.6 x 16 x
FCF Yield 5.2% 6.33% 5.51% 5.17% 3.54% 6.98% 6.01% 6.26%
Price to Book 14.7 x 14.1 x 18.7 x 38.3 x 24.7 x 30.5 x 24 x 25.8 x
Nbr of stocks (in thousands) 594,184 582,169 563,266 533,579 535,178 536,435 - -
Reference price 2 241.1 229.9 225.0 262.6 288.0 314.7 314.7 314.7
Announcement Date 1/30/20 2/2/21 2/7/22 1/31/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 23,362 25,424 25,979 26,323 28,190 33,016 33,978 34,714
EBITDA 1 13,363 15,935 15,822 16,178 17,470 19,098 19,412 19,771
EBIT 1 11,157 12,334 12,424 12,761 13,399 14,828 15,480 15,798
Operating Margin 47.76% 48.51% 47.82% 48.48% 47.53% 44.91% 45.56% 45.51%
Earnings before Tax (EBT) 1 9,138 8,133 6,701 7,346 7,855 4,604 8,649 8,101
Net income 1 7,842 7,264 5,893 6,552 6,717 4,133 6,611 7,022
Net margin 33.57% 28.57% 22.68% 24.89% 23.83% 12.52% 19.46% 20.23%
EPS 2 12.88 12.31 10.28 12.11 12.49 7.734 12.57 13.14
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,165 12,760 13,033
FCF margin 36.52% 38.9% 32.26% 33.37% 26.11% 45.93% 37.55% 37.54%
FCF Conversion (EBITDA) 63.85% 62.06% 52.97% 54.3% 42.12% 79.4% 65.73% 65.92%
FCF Conversion (Net income) 108.8% 136.14% 142.22% 134.08% 109.56% 366.94% 193.02% 185.62%
Dividend per Share 2 5.800 6.400 7.040 7.760 8.520 9.269 9.988 10.53
Announcement Date 1/30/20 2/2/21 2/7/22 1/31/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 6,846 6,238 6,594 6,652 6,839 6,105 6,986 6,903 8,196 7,447 8,319 8,433 8,807 8,099 8,592
EBITDA 1 3,849 3,981 4,163 4,114 3,920 3,721 4,411 4,298 5,040 4,477 5,147 5,302 5,053 - -
EBIT 1 2,997 3,140 3,335 3,277 3,009 2,821 3,515 3,403 3,660 3,078 3,794 3,907 4,025 3,588 3,975
Operating Margin 43.78% 50.34% 50.58% 49.26% 44% 46.21% 50.31% 49.3% 44.66% 41.33% 45.61% 46.33% 45.7% 44.31% 46.27%
Earnings before Tax (EBT) 1 2,131 1,675 1,531 2,392 1,748 3,442 1,614 1,947 852 -68 1,558 1,584 1,538 2,599 2,985
Net income 1 1,899 1,476 1,317 2,143 1,616 2,841 1,379 1,730 767 -113 1,263 1,390 1,247 1,663 1,996
Net margin 27.74% 23.66% 19.97% 32.22% 23.63% 46.54% 19.74% 25.06% 9.36% -1.52% 15.19% 16.49% 14.16% 20.53% 23.23%
EPS 2 3.360 2.680 2.450 3.980 3.000 5.280 2.570 3.220 1.420 -0.2100 2.500 2.739 2.503 3.105 3.740
Dividend per Share 2 1.760 1.940 1.940 1.940 1.940 2.130 2.130 2.130 2.130 2.250 2.305 2.305 2.305 2.580 2.580
Announcement Date 2/7/22 4/27/22 8/4/22 11/3/22 1/31/23 4/27/23 8/3/23 10/31/23 2/6/24 5/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 20,992 22,339 25,272 29,640 53,669 48,469 43,512 39,213
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.571 x 1.402 x 1.597 x 1.832 x 3.072 x 2.538 x 2.242 x 1.983 x
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,165 12,760 13,033
ROE (net income / shareholders' equity) 81.4% 103% 122% 185% 203% 157% 156% 173%
ROA (Net income/ Total Assets) 14.3% 16% 15.8% 15.2% 12.4% 6.32% 7.8% 9.12%
Assets 1 54,778 45,481 37,328 43,230 54,315 65,384 84,801 76,990
Book Value Per Share 2 16.40 16.30 12.00 6.860 11.60 10.30 13.10 12.20
Cash Flow per Share 2 15.00 17.80 16.20 18.00 15.70 20.80 21.50 25.30
Capex 1 618 608 880 936 1,112 1,069 1,048 1,180
Capex / Sales 2.65% 2.39% 3.39% 3.56% 3.94% 3.24% 3.08% 3.4%
Announcement Date 1/30/20 2/2/21 2/7/22 1/31/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Amgen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
314.7 USD
Average target price
314.1 USD
Spread / Average Target
-0.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.12% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 239B
NOVARTIS AG Stock Novartis AG
+10.11% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. Financials Amgen Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW